SG3 Management’s Takeda Pharmaceutical TAK Stock Holding History

SG3 Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$341K	–	1354
2021 Q4	$341K	Buy	+25,000	New	+$351K	0.01%	718
2019 Q2	–	Sell	-111,550	Closed	-$2.27M	–	511
2019 Q1	$2.27M	Buy	+111,550	New	+$2.24M	0.22%	95

Other funds holding TAK

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SG3 Management's TAK Position: Q1 2022 in Review

SG3 Management sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 25,000 shares — an estimated $341K sold.

SG3 Management first reported a position in TAK in Q1 2019 and held it in 2 quarters. The position peaked at $2.27M in Q1 2019. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

SG3 Management reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 25,000 Takeda Pharmaceutical shares in Q1 2022, an estimated $341K.
SG3 Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 2 quarters.
SG3 Management's Takeda Pharmaceutical position peaked at $2.27M in Q1 2019.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.